The Group noticed that certain media published articles on 12 May 2022 purporting that the Group is under negotiation with potential investors in respect of privatization and disclosed relevant information such as valuation and privatization pricing. The Group hereby clarifies that the content of above news reports is not true.
Having made all reasonable enquiries with respect to the Company, the Board confirms that, none of the above reports constitute the inside information (the “Inside Information”) that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), and it is not aware of any information that needs to be disclosed to avoid a false market in the Company’s securities or of any other Inside Information.
The Group reminds investors that the website of The Stock Exchange of Hong Kong Limited
(http://www.hkexnews.hk) is the information disclosure channel designated by the Company and all material information of the Company shall be accessed based on the Company’s official announcements through the said channel. Investors are advised to exercise caution in their investments and pay attention to risks.
By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director
12 May 2022